Working… Menu

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02437279
Recruitment Status : Active, not recruiting
First Posted : May 7, 2015
Last Update Posted : October 19, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
The Netherlands Cancer Institute